Category Archives: Cell Biology

Cell Biology

Top Key-Players To Be Restored To The First Position In The Recombinant Cell Culture Supplements Market The Courier – The Courier

The Recombinant Cell Culture Supplements Market report by Persistence Market Research is focusing on the fact that healthcare providers are into collection of socioeconomic information of the patients, so that tracking at any point of time is possible. This on-the-go monitoring is amongst the ongoing trends in the healthcare industry.

Adoption of recombinant cell culture supplements by biopharmaceutical manufacturers and research institutes has increased significantly for the development of novel drugs and treatment. Growing demand for novel vaccines to treat and prevent severe diseases, as well as increasing stem cell research activities by biopharmaceutical manufactures are likely to pace up the lucrativeness of theglobalrecombinant cell culture supplements market.

Get Sample Copy of Report @https://www.persistencemarketresearch.com/samples/31310

Company Profiles

Recombinant cell culture supplements are gaining higher adoption in mammalian cell production processes in different production units and research centres. Moreover, rising investments in biologics production and growing research for the introduction of innovative gene therapies are bolstering the demand for recombinant cell culture supplements.

The global recombinant cell culture supplements market was valued aroundUS$ 320 Mnin2018, and is expected to exhibit aCAGRof more than6%over the forecast period (20192029).

Get To Know Methodology of Report @https://www.persistencemarketresearch.com/methodology/31310

Key Takeaways of Recombinant Cell Culture Supplements Market Study

Increasing requirement of recombinant cell culture supplements for mammalian cell lines and viral & protein-based vaccines production is likely to pace up market growth. Demand will continue to pick pace, with burgeoning use of supplements in cancer research, tissue regeneration, and gene therapy development,says a PMR analyst.

Product Portfolio Expansion through Acquisitions & Partnerships Key Strategy of Manufacturers

Recombinant cell culture supplement manufacturers are focusing on product portfolio expansion through partnerships and acquisition of small. In 2015, Abcam Plc signed an exclusive partnership agreement with A* STARs Institute of Molecular and Cell Biology to develop high-quality immunoassays for life science research.

Access Full Report @https://www.persistencemarketresearch.com/checkout/31310

More Valuable Insights on Recombinant Cell Culture Supplements Market

Persistence Market Research offers a unique perspective and actionable insights on recombinant cell culture supplements in its latest study, presenting historical demand assessment of20142018and projections for20192029, on the basis of product (recombinant growth factors, recombinant insulin, recombinant albumin, recombinant transferrin, recombinant trypsin, recombinant aprotinin, recombinant lysozyme, and others), application (stem cell therapy, gene therapy, bioprocess application, vaccine development, and others), source (animals, microorganisms, and humans), and end user (academic and research institutes, biopharmaceutical companies, cancer research centers, and contract research centers), across seven major regions.

Explore Extensive Coverage of Persistence Market Researchs Healthcare Industry

About us:

Persistence Market Research (PMR), as a 3rd-party research organization, does operate through an exclusive amalgamation of market research and data analytics for helping businesses ride high, irrespective of the turbulence faced on the account of financial/natural crunches.

Contact us:

Persistence Market ResearchAddress 305 Broadway, 7th Floor, New York City, NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales sales@persistencemarketresearch.com

Excerpt from:
Top Key-Players To Be Restored To The First Position In The Recombinant Cell Culture Supplements Market The Courier - The Courier

Cell Biology

Tissue Repair, Mitochondrial Function and Wound Healing Explored in 2021 APS Presidents Symposium – Newswise

Rockville, Md. (April 22, 2021)Top researchers in physiology will present a three-part series exploring cellular regulation of mitochondrial function, tissue repair and wound healing. The symposia are organized by American Physiological Society (APS) President Linda Samuelson, PhD, FAPS, FAAAS, of the University of Michigan. The APS Presidents Symposium Series will be part of the APS annual meeting at Experimental Biology 2021, which will be held on a virtual platform April 2730.

Function Symposium: Regulation of Physiological Function

Tuesday, April 27, 2 p.m. Virtual Session, Room APS-1

Chair:Ole H. Petersen, CBE, FRS, Cardiff University, U.K.

Speakers:

Functions of presynaptic voltage-gated calcium channels

Annette Dolphin, PhD, FRS, FmedSci, University College London, U.K.

Crosstalk between Ca2+ and cAMP signaling in mitochondria: where, when, why

Tullio Pozzan, MD, FRS, University of Padova, Italy

New perspectives on the physiological roles of KATP channels

Colin Nichols, PhD, FRS, Washington University School of Medicine, St. Louis

The P2X7 receptor is a key modulator of mitochondrial energy metabolism

Francesco Di Virgilio, MD, University of Ferrara, Italy

Adult Cell Plasticity and Tissue Rejuvenation

Wednesday, April 28, 2 p.m. Virtual Session, Room APS-1

Chair: Linda Samuelson, PhD, FAPS, FAAAS, University of Michigan

Speakers:

Switching cell fate to regenerate liver

Stacey S. Huppert, PhD, Cincinnati Childrens Hospital

Exercise rejuvenates aging stem cells

Thomas Rando, MD, PhD, Stanford University, Stanford, California

Cellular remodeling via paligenosis

Jason C. Mills, MD, PhD, Washington University School of Medicine, St. Louis

Cellular Cross-talk to Orchestrate Tissue Repair

Thursday, April 29, 2 p.m. Virtual Session, Room APS-1

Chairs: Linda Samuelson, PhD, FAPS, FAAAS, University of Michigan; Jason C. Mills, MD, PhD, Washington University School of Medicine, St. Louis

Speakers:

Immune mediators and wound healing

Asma Nusrat, MD, University of Michigan

Mesenchymal cells promote lung regeneration

Edward E. Morrisey, PhD, Perelman School of Medicine, University of Pennsylvania

Tissue stem cells: coping with stress

Elaine Fuchs, PhD, Howard Hughes Medical Institute, The Rockefeller University, New York

NOTE TO JOURNALISTS: To schedule an interview with a member of the research team, please contact the APS Communications Office or call 301.634.7314. Find more research highlights in the APS Newsroom.

About Experimental Biology 2021

Experimental Biology is the annual meeting of five societies that explores the latest research in physiology, anatomy, biochemistry and molecular biology, investigative pathology and pharmacology. With a mission to share the newest scientific concepts and research findings shaping clinical advances, the meeting offers an unparalleled opportunity for global exchange among scientists who represent dozens of scientific areas, from laboratory to translational to clinical research.

About the American Physiological Society

Physiology is a broad area of scientific inquiry that focuses on how molecules, cells, tissues and organs function in health and disease. The American Physiological Society connects a global, multidisciplinary community of more than 10,000 biomedical scientists and educators as part of its mission to advance scientific discovery, understand life and improve health. The Society drives collaboration and spotlights scientific discoveries through its 16 scholarly journals and programming that support researchers and educators in their work.

Go here to read the rest:
Tissue Repair, Mitochondrial Function and Wound Healing Explored in 2021 APS Presidents Symposium - Newswise

Cell Biology

Axion BioSystems Announces Formation of Scientific Advisory Board – Business Wire

ATLANTA--(BUSINESS WIRE)--Axion BioSystems, a leading life science tools company focused on developing and commercializing label-free, bioelectronic assays used to study the function of live cells in vitro, announces the formation of a Scientific Advisory Board (SAB). The SAB will be chaired by Jim Ross, Ph.D., founder and Chief Technology Officer, and will work closely with Axion BioSystems management team to help identify and prioritize Axions next generation of bioelectronic products.

We are proud to have such an accomplished and diverse group of scientific experts joining our Scientific Advisory Board. The SABs expertise will be invaluable as we continue expanding our research and development activities, said Tom OBrien, CEO & President of Axion BioSystems.

The members of Axion BioSystems Scientific Advisory Board include:

Christopher Basler, Ph.D., is Professor and Director of the Center for Microbial Pathogenesis at Georgia State University. He obtained his Ph.D. from Albert Einstein College of Medicine in 1995. He became Professor of Microbiology at Icahn School of Medicine at Mount Sinai in New York City in 2013 and moved to Georgia State University in 2016. Dr Basler was elected Fellow of the American Academy of Microbiology in 2014 and was named a Georgia Research Alliance Eminent Scholar in Microbial Pathogenesis in 2016. His major research interests are understanding immune evasion and replication mechanisms of filoviruses, coronaviruses and other emerging RNA viruses.

Evangelos Kiskinis, Ph.D., is an Assistant Professor of Neurology at Northwestern University Feinberg School of Medicine, Director of the Stem Cell Core Facility, and a New York Stem Cell Foundation Robertson Investigator. He received Ph.D. from Imperial College and carried out postdoctoral training at Harvard University where he pioneered the first models of ALS using personalized stem cell-based approaches. Dr Kiskinis discoveries on excitability deficits in patient neurons using induced pluripotent stem cells (iPSCs) led to a clinical trial with a small molecule drug. His laboratory seeks to harness the power of pluripotent stem cells to understand how neuronal function is impaired in ALS/FTD patients and pediatric forms of epilepsy. He has been the recipient of prestigious fellowships from the European Molecular Biology Organization, the New York Stem Cell Foundation and the Charles A. King Trust Medical Foundation.

Alysson Muotri, Ph.D., is a Professor at the Departments of Pediatrics and Cellular & Molecular Medicine at UC San Diego. He is also the Director of the Stem Cell Program and Archealization Center at UCSD. His lab focuses on the re-creation of the human brain using stem cell technologies and brain organoids. Dr. Muotri received his Ph.D. in Genetics in 2001 from University of Sao Paulo, Brazil, and moved to the Salk Institute as Pew Latin America Fellow in 2002 for postdoctoral training in the fields of neuroscience and stem cell biology. His research focuses on brain evolution and modeling neurological diseases using human induced pluripotent stem cells and brain organoids. He has received several awards, including the prestigious NIH Directors New Innovator Award, NARSAD, Emerald Foundation Young Investigator Award, Surugadai Award, Rock Star of Innovation, NIH EUREKA Award, Telly Awards among several others.

Manu Platt, Ph.D., is a Professor at the Wallace H. Coulter Department of Biomedical Engineering at Georgia Institute of Technology & Emory University. He received his Ph.D. from Georgia Tech/Emory joint program in Biomedical Engineering, and carried out postdoctoral training at MIT. Currently, his lab focuses on pediatric strokes in sickle cell disease and personalized and predictive medicine strategies for breast cancer. Dr Platts work has been successfully funded by NIH Directors New Innovator Award, International AIDS Society, Georgia Cancer Coalition, and the National Science Foundation. Dr. Platt was inducted as inducted as a Fellow of the American Institute for Medical and Biological Engineering (AIMBE) in 2019. Integrated with his research program are his mentoring goals of changing the look of the next generation of scientists and engineers to include all colors, genders, and backgrounds. Aligned with that goal, Dr. Platt co-founded Project ENGAGES (Engaging the Next Generation At Georgia Tech in Engineering and Science), with Dr. Bob Nerem in 2013.

Jiwen Zhang, Ph.D., is Vice President of Regulatory Affairs at Passage Bio, Inc. Before joining Passage Bio, she had worked at Tmunity, GE Healthcare and biopharmaceutical companies including Johnson & Johnson, Merck, Wyeth Pharmaceuticals, and Sanofi-Aventis. Dr. Zhang has extensive experience in regulatory development across multiple therapeutic areas, including anti-inflammatory, anti-viral, metabolic, hematology, bone and growth. She has also had experience in developing drug/device combination products, and medical devices used at cell therapy point of care setting. She is leading various industry initiatives through the Standards Coordinating Body, the International Standards Organization (ISO), CASSS, and Asia Pacific Economic Cooperation Regulatory Harmonization Steering Committee (APEC RHSC). Dr. Zhang obtained her Ph.D. in Neuroscience from the joint program at the Rutgers University and the University of Medicine and Dentistry of New Jersey.

For more information, please visit https://www.axionbiosystems.com/scientific-advisory-board.

About Axion BioSystems, Inc.

Axion, a life science company located in Atlanta, GA, developed the first commercial multi-well MEA system, the Maestro, an easy-to-use, non-invasive instrument that measures functional electrical signals from brain and heart cells. Axion have continued to expand on the promise of these label free, bioelectronic assays. Recently, Axion introduced the Maestro Z and ZHT systems, providing functional measures of cell growth, with specific applications in immuno-oncology and virology. Axions products are used by pharmaceutical and biotech companies, governmental agencies, and universities for disease modeling, drug safety, and drug discovery assays.

See the original post:
Axion BioSystems Announces Formation of Scientific Advisory Board - Business Wire

Cell Biology

Global Cell Therapy Market By Therapy Type, By Therapeutic Area, By End User, By Cell Type, By Regional Outlook, Industry Analysis Report and…

The Global Cell Therapy Market size is expected to reach $28. 5 billion by 2026, rising at a market growth of 26. 2% CAGR during the forecast period. Cell therapy is considered as a technology that is based on substituting dysfunctional or diseased cells with active & functional cells.

New York, April 22, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Cell Therapy Market By Therapy Type, By Therapeutic Area, By End User, By Cell Type, By Regional Outlook, Industry Analysis Report and Forecast, 2020 - 2026" - https://www.reportlinker.com/p06064792/?utm_source=GNW Stem cells possess the capability to differentiate into particular cells needed for repairing damaged or defective tissues or cells, thats why they are utilized for these advanced therapies. In addition, cell therapy is used in the development of regenerative medicines, which is an interdisciplinary domain aimed at maintenance, enhancement, or restoration of cell, tissue, organ function with the help of procedures majorly associated with cell therapy.

Moreover, cells like bone marrow and blood cells, mature, immature & solid tissue cells, adult stem cells, and embryonic cells are extensively deployed in cell therapy methods. Further, transplanted cells involve embryonic stem cells (ESCs), pluripotent stem cells (iPSCs), neural stem cells (NSCs), and mesenchymal stem cells (MSCs) are bifurcated mainly two groups viz. Allogeneic cell therapy and non-Allogeneic cell therapy.

At present, there are two types of cell therapies exist. The first type is cell therapy in mainstream medicine. This category includes human embryonic stem cell therapy, mesenchymal stem cell therapy, neural stem cell therapy, Autologous cell therapy, and hematopoietic stem cell therapy. The second category is in alternative medicine and perpetuates the practice of injecting animal materials in an effort to cure diseases. This practice, as per the American Cancer Society, is not supported by any medical proof of efficiency and can have fatal results.

The outbreak of the COVID-19 pandemic has affected many biopharmaceutical units, while many cellular therapy development organizations have observed a severe impact, which is due to the complexities in logistics and manufacturing models used in this sector. Moreover, considerable and constant investment is essential to allow effective commercial translation of cell-based therapeutics, an aspect that was negatively affected in 2020, further affected the overall market growth.

Therapy Type Outlook

Based on Therapy Type, the market is segmented into Autologous and Allogeneic. The Autologous therapies segment would show gradual growth due to the massive cost associated with Autologous transplants and comparatively less relapse rates. Though, development in cell banking and companies switch towards the creation of allogenic therapy products is boosting the cell therapy market.

Therapeutic Area Outlook

Based on Therapeutic Area, the market is segmented into Malignancies, Autoimmune Disorders, Musculoskeletal Disorders, Dermatology and Others. The Malignancies market dominated the Global Cell Therapy Market by Therapeutic Area 2019, growing at a CAGR of 25.2 % during the forecast period. The Autoimmune Disorders market is experiencing a CAGR of 27.6% during (2020 - 2026). Additionally, The Musculoskeletal Disorders market would showcase a CAGR of 27.2% during (2020 - 2026).

End User Outlook

Based on End User, the market is segmented into Academic & Research Institutes and Hospitals & Clinics. In 2019, the Academic & Research Institutes segment emerged as the leading segment of the market and held the highest revenue share. The stem cells are significantly being utilized for research projects, which as a result, has contributed to a massive revenue share for the Academic & Research Institutes segment. The segment would show a similar trend during the forecast period.

Cell Type Outlook

Based on Cell Type, the market is segmented into Stem Cell, Umbilical Cord-Derived, Adipose-Derived Stem Cell, Non-Stem Cell, Bone Marrow, Blood and Others. The Stem Cell market dominated the Global Cell Therapy Market by Cell Type 2019, and would continue to be a dominant market till 2026. The Umbilical Cord-Derived market is expected to witness a CAGR of 27.7% during (2020 - 2026).

Regional Outlook

Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. In 2019, North America emerged as the leading region of the global cell therapy market by obtaining the highest revenue share. The larger share of the region is due to the existence of a considerable number of centers and institutes that are undergoing R&D activities to stem cell therapy. Among the top universities in the world, 5 are based in the U.S., including Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Harvard Stem Cell Institute, Harvard University, and Yale Stem Cell Center.

The major strategies followed by the market participants are Partnerships. Based on the Analysis presented in the Cardinal matrix; Fujifilm Holdings Corporation is the major forerunner in the Cell Therapy Market. Companies such as JCR Pharmaceuticals Co., Ltd., NuVasive, Inc., Medipost Co., Ltd., Vericel Corporation, and Avantor, Inc. are some of the key innovators in the market.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Fujifilm Holdings Corporation, Smith & Nephew PLC, Kolon TissueGene, Inc., JCR Pharmaceuticals Co., Ltd., Medipost Co., Ltd., Stemedica Cell Technologies, Inc., NuVasive, Inc., Avantor, Inc., Vericel Corporation, and Pharmicell Co., Ltd.

Recent strategies deployed in Cell Therapy Market

Partnerships, Collaborations, and Agreements:

Mar-2021: Fujifilm collaborated with Sana Biotechnology, a biotechnology company. Under this collaboration, Sana has permitted a non-exclusive right to utilize the Fujifilm Cellular Dynamics iPSC platform for the development of commercial cell therapies. Cell therapies as a treatment modality can boost, repair, or replace human biology that includes tissues, organs, and cells.

Nov-2020: Fujifilm came into partnership with Lonza Walkersville, a leading global GMP iPSC manufacturer. In this partnership, Fujifilm Cellular Dynamics permitted Lonza a non-exclusive right to utilize their patents related to iPSC generation, which include episomal vectors and reprogramming factors, for the clinical production and differentiation of iPSC lines for cell therapies.

Apr-2020: Fujifilm Diosynth Biotechnologies (FDB) entered into a partnership with OXGENE, an industry leader in the design and development of gene therapy technologies. The partnership enables FDB to provide gene therapy products to customers with an approximate 25% lead-time reduction.

Jun-2019: JCR Pharmaceuticals extended the partnership with Mesoblast Limited, an Australian-based regenerative medicine company. This expansion aimed to utilize mesenchymal stem cells (MSCs) for curing newborns who have insufficient blood supply and oxygen to the brain, this condition is termed neonatal hypoxic-ischemic encephalopathy (HIE).

Jan-019: Medipost signed a cooperation agreement with LG Chem, the largest Korean chemical company. In this agreement, both companies conducted research to discover a stem cell drug candidate for the next two years. Medipost would be responsible for making and delivering umbilical cord blood-derived mesenchymal stem cells and LG Chem has taken charge in choosing the genes, which cause disease and stem cell generation utilizing the genetic engineering techniques

Acquisition and Mergers:

Apr-2020: JCR Pharmaceuticals acquired ArmaGen, Inc., a privately-held US biopharmaceutical company. This acquisition is a testament to the companys robust commitment to bring advanced medicines to patients with mucopolysaccharidoses and other LSDs.

Mar-2019: Smith & Nephew came into agreement to acquire Osiris Therapeutics, a fast-growing company delivering regenerative medicine products. This acquisition will improve Smith & Nephews portfolio and help instantly boost their wound management business and also offer longer-term innovations in additional channels and indications.

Product Launches and Product Expansions:

Sep-2020: Smith & Nephew introduced the HEALICOIL KNOTLESS Suture Anchor. This launch expanded its revolutionary portfolio of Advanced Healing Solutions for rotator cuff repair. This line of a product consists of the innovative REGENETEN Bioinductive Implant and novel REGENESORB Material. These are developed to support a jump start in bone healing and formation.

Mar-2020: Avantor Performance Materials introduced a new recombinant Protein A affinity chromatography resin. It is a proven downstream purification step in producing mAbs. This new Avantor recombinant protein A resin helps in coping up with these challenges.

Jul-2019: NuVasive introduced its Pulse platform. This platform integrated various technologies into multiple spine surgery procedures, which include corrections, bone fusions, and more. The modular workflow product line encompasses surgical planning, patient-specific rod bending, and 2D and 3D imaging and also alignment, navigation, neurological monitoring, and radiation reduction at the time of operation.

Jan-2019: Fujifilm Cellular Dynamics unveiled iCell Microglia. It is the immune cells of the central nervous system helps in fundamental physiological and pathological processes. The iCell Microglia is different from human iPSCs is utilized in life science research to allow the study and development of therapies for degenerative neurological diseases like Alzheimers disease.

Geographical Expansions:

Jun-2020: Avantor expanded its Bridgewater, N.J. (USA) innovation center. This expansion improved the Companys R&D support for a personalized product and bioprocess development, and custom cell & gene therapy reagent production to support the customers therapeutic products, which are developed for improvements in customized medicines.

Dec-2019: Avantor expanded its global presence by opening an innovation and customer support center in Shanghai, China. This center supports biopharma research and technology development in the region. With this expansion, Avantor has nine innovation centers across the globe. The new Avantor laboratory helps the biopharmaceutical companies to escalate the development of life-changing treatments for patients in the region.

Jan-2019: Fujifilm Cellular Dynamics, a US subsidiary of Fujifilm Corporation expanded its geographical footprints by establishing a new cGMP-compliant production facility. This expansion aimed to improve its production of iPS cells for cell therapy.

Scope of the Study

Market Segments covered in the Report:

By Therapy Type

Autologous

Allogeneic

By Therapeutic Area

Malignancies

Autoimmune Disorders

Musculoskeletal Disorders

Dermatology

Others

By End User

Academic & Research Institutes

Hospitals & Clinics

By Cell Type

Stem Cell

Umbilical Cord-Derived

Adipose-Derived Stem Cell

Non-Stem Cell

Bone Marrow

Blood

Others

By Geography

North America

o US

o Canada

o Mexico

o Rest of North America

Europe

o Germany

o UK

o France

o Russia

o Spain

o Italy

o Rest of Europe

Asia Pacific

o China

o Japan

o India

o South Korea

o Singapore

o Malaysia

o Rest of Asia Pacific

LAMEA

o Brazil

o Argentina

o UAE

o Saudi Arabia

o South Africa

o Nigeria

o Rest of LAMEA

Companies Profiled

Fujifilm Holdings Corporation

Smith & Nephew PLC

Kolon TissueGene, Inc.

JCR Pharmaceuticals Co., Ltd.

Medipost Co., Ltd.

Stemedica Cell Technologies, Inc.

NuVasive, Inc.

Avantor, Inc.

Vericel Corporation

Pharmicell Co., Ltd.

Unique Offerings

See the rest here:
Global Cell Therapy Market By Therapy Type, By Therapeutic Area, By End User, By Cell Type, By Regional Outlook, Industry Analysis Report and...

Cell Biology

The Mesenchymal Stem Cells Market To Grow In Direct Proportion With Innovations KSU | The Sentinel Newspaper – KSU | The Sentinel Newspaper

The Mesenchymal Stem Cells Market report by Persistence Market Research is focusing on the fact that healthcare providers are into collection of socioeconomic information of the patients, so that tracking at any point of time is possible. This on-the-go monitoring is amongst the ongoing trends in the healthcare industry.

How about looking through the sample of Mesenchymal Stem Cells market report?https://www.persistencemarketresearch.com/samples/3309

North America dominates the global market for mesenchymal stem cell due to large number of aging population and increasing incidence of cancers. Asia is expected to show high growth rates in the next five years in the global mesenchymal stem cell market. China and India are expected to be the fastest growing mesenchymal stem cell markets in Asia-Pacific region. Some of the key driving forces for mesenchymal stem cell market in emerging countries are large pool of patients and rising government funding and support.

Want a sneak peek into the Mesenchymal Stem Cells market? Access the Table of Content of Mesenchymal Stem Cells market report!https://www.persistencemarketresearch.com/toc/3309

In recent times there is increased use of mesenchymal stem cell due to increasing aging population. Rising incidence of chronic diseases, regulatory and government support and increasing investment in stem cell biology are some of the key factors driving the growth for the global mesenchymal stem cell market. In addition, increasing use of mesenchymal stem cell as a substitute to knee replacement surgeries and other operative procedures is also fuelling the growth of the global mesenchymal stem cell market. However, lack of therapeutic advancement related to vitro properties of stem cell is the major factor restraining the growth for the global mesenchymal stem cell market.

Planning to enter the arena of Mesenchymal Stem Cells market? Prebook our Mesenchymal Stem Cells market report!https://www.persistencemarketresearch.com/checkout/3309

Numerous ethical, political and religious controversies on mesenchymal stem cell could lead a challenge for the global mesenchymal stem cell market. Some of the trends for the global mesenchymal stem cell market are increasing collaborations and partnerships and rising innovation of mesenchymal stem cell products. Some of the major companies operating in the global mesenchymal stem cell market are EMD Millipore Corporation, Cell Applications, Inc., Cyagen Biosciences, Inc., Genlantis, Inc., Advanced Cell Technology Incorporated, Stemcell Technologies Inc., Celprogen, Inc., Stemedica Cell Technologies, Aastrom Biosciences and ScienCell Research Laboratories.

Explore Extensive Coverage of Persistence Market ResearchsHealthcare Industry

About us:

Persistence Market Research (PMR), as a 3rd-party research organization, does operate through an exclusive amalgamation of market research and data analytics for helping businesses ride high, irrespective of the turbulence faced on the account of financial/natural crunches.

Contact us:

Persistence Market ResearchAddress 305 Broadway, 7th Floor, New York City, NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales sales@persistencemarketresearch.com

Read more from the original source:
The Mesenchymal Stem Cells Market To Grow In Direct Proportion With Innovations KSU | The Sentinel Newspaper - KSU | The Sentinel Newspaper

Cell Biology

Anavo Therapeutics wants Big Pharma to dust off the shelves in search of phosphatase drugs – FierceBiotech

Brand-new biotech Anavo Therapeutics knows Big Pharma has been burned by a so-called undruggable target calledphosphatases, but it's here to help now.

The company launchedtoday out of the Netherlands with 20 million ($24 million) in seed funding, ready to give this strongly neglected drug target the attention it deserves.

The seed financing was led by M Ventures and INKEF Capital as well as Taiho Ventures and Bioqube Ventures. Anavo plans to use the money to develop a proprietary drug discovery platform in oncology to finally elevate phosphatase medicines.

Phosphatases first rose to prominence in the pharmaceutical world 25 years ago when attention turned to modulating signal transduction in cells as a way to stop disease, particularly cancer. Phosphatases and kinases regulate activity of signaling pathways in cells by removing or adding a phosphate group from proteins or other molecules. If this system gets out of whack, a multitude of diseases including cancer and diabetes can proliferate.

Early research suggested that the kinase protein turned on these signaling mechanisms, while phosphatases shut things off in a cell. The focus shifted to kinase inhibitors because they were the actionable side of the transaction, and a drug class was born: Eli Lillys Olumiant for rheumatoid arthritis and Roches Rozlytrek for ROS1-positive non-small cell lung cancer and NTRK fusion-positive tumors are just two of the many examples of drugs on the market from this class already.

Phosphatases emerged as a promising target in diabetes with research suggesting the target could create small-molecule anti-diabetics, rendering insulin obsolete. The pharmaceutical industry went all in, with Novartis, AstraZeneca, Vertex and Incyte all simultaneously discovering two molecules that could be a breakthrough. But that venture failed spectacularly, according to Anavos Chief Scientific Officer Gerhard Mller, Ph.D.

That was truly the Waterloo of the phosphatase family, because billions of research funds were burned. Many, many careers were destroyed, Mller said. These people are still around in the pharma companies these days, so they still have got the hesitation.

Anavo now believes they have the science sorted out, and its time to take another hard look at phosphatases. The initial thinkingkinases turn things on and phosphatases turn them offwas incorrect.

The industry stopped 20 years ago showing interest in that target family, but of course the entire academic world continued, Mller said. Anavo has mined a rich network of scientists to stack its advisory board, including Europes Mr. Phosphatase, Mathieu Bollen, who is a professor of molecular cell biology at the University of Leuven, and Nicholas Tonks, Ph.D., a professor of cancer research at Cold Spring Harbor Laboratory.

Through Bollen and Tonks, Mller said Anavo has access to a whole treasure box of validated targets. Oncology will be the initial focus for the companys in-house drug development, but the company plans to export its expertise, according to CEO Birgit Zech, Ph.D.

Signaling is involved in all kinds of biology, so also in all kinds of disease, she said.

Rather than pursue indications outside its wheelhouseZech said the startup has no business delving into CNS disorders, for exampleAnavo would be happy to work with any pharma companies that may have phosphatase targets collecting dust somewhere, afraid to reopen the file.

What they typically do, they shelve them because they've burned their fingers in the past, and who wants to be the first person who raises their hand and says, 'Hey, here's a new phosphatase!' Zech said. Anavo could also seek partnerships such as licensing deals on any targets they develop that could be promising in indications outside of oncology.

Anavo is not the only name in the phosphatase game, although the new company plans to take a broader look at the class rather than at one or two potential molecules.

RELATED:Sanofi bags rights to Revolutions SHP2 cancer drug

Novartis has three pipeline projects in early-stage development for a SHP2 inhibitor called TNO155 in solid tumors. Mller also noted a partnership between Revolution Medicines and Sanofi on a very similar molecule they call RMC-4630. Hes not sure how the two competing projects will work togetheror notin terms of intellectual property.

The SHP2 partnership was worth $50 million upfront for Revolution with $500 million in potential milestones. Research conducted by Revolution has shown that SHP2 appears to play a role in cancer growth in up to 45% of non-small cell lung cancers, as well as colorectal and ovarian cancers as well as melanoma. RMC-4630 is currently being tested in a phase 1/2 clinical trial.

View original post here:
Anavo Therapeutics wants Big Pharma to dust off the shelves in search of phosphatase drugs - FierceBiotech

Cell Biology

Columbia researchers uncover COVID-19’s impact on brain | – University Business

The team's findings suggest inflammation may trigger neurologic damage but the virus' long-term impact on memory and mood is still unknown.

Higher education institutions have played a critical role in assisting on the front lines and behind the scenes during the COVID-19 pandemic. From vaccine development to clinic rollouts to research around the novel coronavirus, scientific and medical developments have paved the way for strategic decisions to be made on campuses, in communities and across the globe.

Some of those breakthroughs not only have helped in the moment but also will provide a working base for further discoveries and planning, around this crisis and others in the future.

Late last week, in the publication Brain, a neurology team at Columbia Universitys Vagelos College of Physicians and Surgeons revealed major findings in studies done at Irving Medical Center/New York Presbyterian Hospital. In more than three dozen patients who had contracted the virus and died, all of them had sustained significant neurologic effects from SARS-COV-2.

We observed many pathological changes in these brains, which could explain why severely ill patients experience confusion and delirium and other serious neurological effects, and why those with mild cases may experience brain fog for weeks and months, said Dr. James Goldman, professor of pathology and cell biology in psychiatry, who led the study along with professors Dr. Peter Canoll and Dr. Kiran Thakur.

They also made another important discovery.

Theres been considerable debate about whether this virus infects the brain, but we were unable to find any signs of virus inside brain cells of more than 40 COVID-19 patients, Goldman said.

Inside the report

The study was conducted on 41 patients age 38 to 97 who had been hospitalized before losing their battles to COVID-19. Some died soon after being admitted, while others passed away after months of fighting the virus. Researchers noted that about half of the patients had been intubated. In addition to the damage done to the brain, they all experience lung damage, one of the hallmarks of COVID-19.

The first thing we noticed was a lot of areas with damage from a lack of oxygen, Goldman said. They all had severe lung disease, so its not surprising that theres hypoxic damage in the brain.

Researchers noted that blood clots likely caused the hypoxic damage. In addition, Canoll said microglia, or dormant immune cells in the brain that can be triggered by diseases, were seen often in patents. It is likely the inflammation throughout the body caused those cells to be activated, so even without directly infecting brain cells, COVID-19 can cause damage to the brain, he said.

One concern is the potential long-term effects of those who have gotten the virus and the length of time their bodies may have been fighting COVID-19. Since they were found mainly in the lower brain stem area, could the movement of microglia affect memory and mood?

We know the microglia activity will lead to loss of neurons, and that loss is permanent, Goldman says. Is there enough loss of neurons (in the hippocampus) to cause memory problems? Or in other parts of the brain that help direct our attention? Its possible, but we really dont know at this point.

So, Columbia researchers will continue to study patterns. They are currently looking at those who recovered from COVID-19 but then passed away as well as patients who had pre-existing respiratory issues to determine how much of COVID-19 brain pathology is a result of the severe lung disease.

See more here:
Columbia researchers uncover COVID-19's impact on brain | - University Business

Cell Biology

Artificial intelligence model predicts which key of the immune system opens the locks of coronavirus – Newswise

Newswise The human immune defense is based on the ability of white blood cells to accurately identify disease-causing pathogens and to initiate a defense reaction against them. The immune defense is able to recall the pathogens it has encountered previously, on which, for example, the effectiveness of vaccines is based. Thus, the immune defense the most accurate patient record system that carries a history of all pathogens an individual has faced. This information however has previously been difficult to obtain from patient samples.

The learning immune system can be roughly divided into two parts, of which B cells are responsible for producing antibodies against pathogens, while T cells are responsible for destroying their targets. The measurement of antibodies by traditional laboratory methods is relatively simple, which is why antibodies already have several uses in healthcare.

"Although it is known that the role of T cells in the defense response against for example viruses and cancer is essential, identifying the targets of T cells has been difficult despite extensive research," says Satu Mustjoki, Professor of Translational Hematology.

AI helps to identify new key-lock pairs

T cells identify their targets in a key and a lock principle, where the key is the T cell receptor on the surface of the T cell and the key is the protein presented on the surface of an infected cell. An individual is estimated to carry more different T cell keys than there are stars in the Milky Way, making the mapping of T cell targets with laboratory techniques cumbersome.

Researchers at Aalto University and the University of Helsinki have therefore studied previously profiled key-lock pairs and were able to create an AI model that can predict targets for previously unmapped T cells.

"The AI model we created is flexible and is applicable to every possible pathogen - as long as we have enough experimentally produced key-lock pairs. For example, we were quickly able to apply our model to coronavirus SARS-CoV-2 when a sufficient number of such pairs were available," explains Emmi Jokinen, M.Sc. and a Ph.D. student at Aalto University.

The results of the study help us to understand how a T cell applies different parts of its key to identify its locks. The researchers studied which T cells recognize common viruses such as influenza-, HI-, and hepatitis B -virus. The researchers also used their tool to analyze the role of T-cells recognizing hepatitis B, which had lost their killing ability after the progression of hepatitis to hepatic cell cancer.

The study has been published in the scientific journalPLOS Computational Biology.

A new life for published data with novel AI models

Tools generated by AI are cost-effective research topics.

"With the help of these tools, we are able to make better use of the already published vast patient cohorts and gain additional understanding of them," points out Harri Lhdesmki, Professor of Computational Biology and Machine Learning at Aalto University.

Using the artificial intelligence tool, the researchers have figured out, among other things, how the intensity of the defense reaction relates to its target in different disease states, which would not have been possible without this study.

"For example, in addition to COVID19 infection, we have investigated the role of the defense system in the development of various autoimmune disorders and explained why some cancer patients benefit from new drugs and some do not", reveals M.D. Jani Huuhtanen, a Ph.D. student at the University of Helsinki, about the upcoming work with the new model.

###

View post:
Artificial intelligence model predicts which key of the immune system opens the locks of coronavirus - Newswise

Cell Biology

The Microfluidic Devices Market To Traverse The Exponential Growth Trajectory Between 2021 The Courier – The Courier

According to a new market report published by Persistence Market Research Global Market Study on Microfluidic Devices: Asia to Witness Highest Growth by 2019 the global microfluidic device market was valued atUSD 1,531.2 million in 2013and is expected to grow at aCAGR of 22.8%from 2013 to 2019, to reach an estimated value ofUSD 5,246.4 million in 2019.

Globally, the microfluidic device market is witnessing significant growth due to increasing R&D investment in pharmaceuticals, life science and rising point of care testing demand. New trends in healthcare, such as health care at home, supports point of care testing (POCT) as the most efficient and effective delivery of healthcare. Miniaturization also reduces the cost for screening compounds in pharmaceutical companies for cell biology problems.

Get Sample Copy of Report @https://www.persistencemarketresearch.com/samples/2995

Some of the major players in the Microfluidic Device market:

Get To Know Methodology of Report @https://www.persistencemarketresearch.com/methodology/2995

In addition, microfluidic proteomic devices are increasingly being used to quantify and identify proteins and to study interactions of different proteins with reagent in array. Different materials such as glass, silicon, polymer metal and ceramics, are used to manufacture microfluidic devices. The global microfluidic device market was valued at USD 1,531.2 million in 2013. It is likely to grow at aCAGR of 22.8%during 2013 to 2019 to reachUSD 5,246.4 millionin 2019.

In North America, rising aging population, increasing health awareness, rising chronic and lifestyle diseases, technological developments for various home use applications, and proper insurance coverage are driving the use of microfluidic devices in the market. Usage of microfluidic technology in North America is high compared to other regions of the world due to its early adoption and multiple applications in different industries.

Access Full Report @https://www.persistencemarketresearch.com/checkout/2995

In Europe, the microfluidic device market is driven by rising diagnostic requirements due to increasing lifestyle associated diseases, aging population and improving healthcare infrastructure. On the other hand, increasing healthcare costs has shifted the focus of healthcare from hospitals to home, which would increase the use of microfluidic devices in the region.

However, Asia is becoming one of the most attractive markets for medical device companies. The growth for microfluidic devices is much faster than developed countries due to widening health insurance penetration and up-gradation of health care systems. Asia is one of the producers of generic drugs, which require microfluidic devices for toxicity testing of drugs.

About us:

Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers experience by acting as the missing link between customer relationships and business outcomes. The best possible returns are assured therein.

Contact us:

Persistence Market ResearchAddress 305 Broadway, 7th FloorNew York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Salessales@persistencemarketresearch.comWebsite https://www.persistencemarketresearch.com

Read this article:
The Microfluidic Devices Market To Traverse The Exponential Growth Trajectory Between 2021 The Courier - The Courier

Cell Biology

AgeX Therapeutics to Collaborate with The Ohio State University to Generate Proof-of-Concept Animal Data for AgeX’s Brown Adipose Tissue (BAT) Cell…

ALAMEDA, Calif.--(BUSINESS WIRE)-- AgeX Therapeutics, Inc.. (AgeX; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today a research collaboration with The Ohio State University using AgeXs brown adipocyte tissue (BAT) cell therapy candidate AgeX-BAT1 in mice to determine whether transplantation of AgeX-BAT1 cells may improve diet-induced obesity, metabolic health including glucose metabolism, and cardiac function.

The research will be conducted in the laboratory of world-leading BAT researcher Kristin Stanford, Ph.D., Associate Professor in Physiology & Cell Biology and Associate Director of the Diabetes and Metabolism Research Center at The Ohio State University Wexner Medical Center. As an early pioneer in BAT transplantation, Dr. Stanford transplanted BAT from donor mice into recipient mice. By 812 weeks post transplantation, recipient mice had improved glucose tolerance, increased insulin sensitivity, lower body weight, reduced fat mass, and a full reversal of high-fat diet-induced insulin resistance (J Clin Invest 2013;123:215-23). This year, Dr. Stanford became the first person to show a direct role for BAT to enhance cardiac function (Circulation 2021;143:145-159).

We will be investigating the potential of human pluripotent stem cell-derived brown adipose tissue (BAT) to improve metabolic health and cardiac function, said Dr. Stanford. The preclinical research studies may provide the basis for future therapeutic interventions in diabetes and obesity as well as provide new insights into the role of BAT.

AgeXs BAT cells may have advantages over other sources of BAT given published data show that AgeXs pioneering PureStem cell derivation and manufacturing technology platform is able to generate highly pure and scalable BAT cells, potentially providing an unlimited source of cells (Stem Cell Res Ther 2019;10:7). AgeX-BAT1 consists of BAT progenitor cells that are capable of becoming BAT.

We are delighted to collaborate with Dr. Kristin Stanford, who has dedicated her career to understanding brown adipose tissue (BAT). The research could generate proof-of-concept data in an animal model for AgeXs BAT cell therapy candidate AgeX-BAT1, said Dr. Nafees Malik, Chief Operating Officer of AgeX. AgeXs BAT cells may offer an innovative therapeutic strategy for diabetes and obesity, which present potential multi-billion-dollar market opportunities, given 13% of adults in the U.S. suffer from diabetes and 42% from obesity.

About AgeX Therapeutics

AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging. Its PureStem and UniverCyte manufacturing and immunotolerance technologies are designed to work together to generate highly-defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a variety of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeXs revolutionary longevity platform induced Tissue Regeneration (iTR) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. AgeX is developing its core product pipeline for use in the clinic to extend human healthspan and is seeking opportunities to establish licensing and collaboration agreements around its broad IP estate and proprietary technology platforms.

For more information, please visit http://www.agexinc.com or connect with the company on Twitter, LinkedIn, Facebook, and YouTube.

Forward-Looking Statements

Certain statements contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as will, believes, plans, anticipates, expects, estimates should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of AgeX Therapeutics, Inc. and its subsidiaries particularly those mentioned in the cautionary statements found in more detail in the Risk Factors section of AgeXs Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commissions (copies of which may be obtained at http://www.sec.gov). Further, in the case of AgeXs new AgeX-BAT1 arrangement with The Ohio State University, there can be no assurance that: (i) the outcome of the research will demonstrate that transplantation of AgeX-BAT1 cells may improve diet-induced obesity, metabolic health including glucose metabolism, and cardiac function, (ii) AgeX-BAT1 cells derived for therapeutic use will be shown to be safe and effective in clinical trials, and (iii) that if any AgeX-BAT1 cells are derived for therapeutic use, those cells will be successfully commercialized even if clinical trials are successful. Subsequent events and developments may cause these forward-looking statements to change. AgeX specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210310005228/en/

See original here:
AgeX Therapeutics to Collaborate with The Ohio State University to Generate Proof-of-Concept Animal Data for AgeX's Brown Adipose Tissue (BAT) Cell...